PMC:4561322 / 1437-3138 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/4561322","sourcedb":"PMC","sourceid":"4561322","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4561322","text":"Qishen Yiqi formula (QSYQ), consisting of Radix Salvia miltiorrhiza, Panax notoginseng, Dalbergia odorifera, and Astragalus membranaceus, has the effect of tonifying Qi, promoting blood circulation and relieving pain, and hence it has been widely used to treat the cardiovascular diseases with Qi deficiency and blood stasis syndrome [1, 2]. Pharmacological researches have shown that the mechanism of QSYQ is related to improve myocardial function, inhibit platelet aggregation, prevent enlargement of end-diastolic diameter, and slow down ventricular remodeling [3–7]. However, the mechanism of QSYQ was mostly elucidated macroscopically by pharmacology indexes of animal experiments or clinical trials. For example, Tong et al. [6] had reported that the myocardial protection function of QSYQ may relate to the reduction of myocardial cell apoptosis in adriamycin-induced cardiomyopathy animal model. The research of Cui et al. [7] had shown that, by detecting clinical indexes which included the right ventricular end-diastolic volume (RVEDV), end-systolic volume (RVESV), stroke volume (SV), and right ventricular ejection fraction (RVEF), QSYQ could significantly improve the right heart function on patients undergoing valve replacement. The findings of these studies explain the action mechanism of QSYQ to some extent, but the further study of QSYQ is still to be done. Up to now, the mechanism of QSYQ to tonify Qi and promote blood circulation is rarely reported at molecular or systems level. In this study, the mechanism of QSYQ was illuminated by the network analysis approach which has the advantage of evaluating TCM's pharmacological effect as a whole unity at molecular level [8, 9].","tracks":[]}